On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Dan Paterson, President and CEO of Verastem, Inc. (NASDAQ:VSTM), a clinical-stage biopharmaceutical company with a market capitalization of $273 million, recently sold 858 shares of the company's ...

Global markets have recently experienced a mix of volatility and growth, with U.S. stocks facing challenges from competitive pressures in the AI sector and political uncertainties surrounding tariffs, ...

The business is also an active participant with the retail giant's Project Gigaton. The initiative aims to engaging suppliers, NGOs and other stakeholders to remove 1 billion metric tons of greenhouse ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

Nanobubble Technology Potentially Increases Yield by 55% and Reduces Harvest Cycle by 30%, Revolutionizing Sustainable ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.